Clinical value of neoadjuvant chemotherapy in the treatment of local advanced cervical cancer
10.3760/cma.j.issn.1008-1372.2010.08.006
- VernacularTitle:评价新辅助化疗用于局部晚期宫颈癌手术治疗前的临床价值
- Author:
Yu ZHANG
;
Xiaomao LI
;
Yuebo YANG
;
Mao LIU
;
Yiran TAO
;
Yu ZHOU
;
Qiang ZHAO
- Publication Type:Journal Article
- Keywords:
Chemotherapy,adjuvant;
Uterine cervical neoplasms/TH
- From:
Journal of Chinese Physician
2010;12(8):1029-1032
- CountryChina
- Language:Chinese
-
Abstract:
Objectives To evaluate the clinical value of neoadjuvant chemotherapy (NACT) in the treatment of local advanced cervical cancer. Methods We searched the clinical trials on the treatment of local advanced cervical cancer with NACT followed by surgery versus initial surgery on English and Chinese published literatures from the main medical data resources (MEDLINE, PUBMED, ELSEVIER ScienceDirect, CNKI). The data about positive pelvic nodes, interstitial infiltration, vascular invasion, positive surgical margin, 3-year overall survival (OS), 3-year disease-free survival (DFS), 5-year OS, 5-year DFS were extracted from these papers, and a meta-analysis was applied. Result The hazard ratio (HR) of positive pelvic nodes on NACT group versus control group was 0. 54(95% CI 0. 33 ～0. 86), HR of interstitial infiltration was 0. 45(95% CI 0. 24 ～0. 86), HR of vascular invasion was 0. 25(95% CI 0. 16 ～0. 38), all differences were statistically significant. And HR of positive surgical margin was 0. 45 ( 95% CI 0. 21 ～0. 99), P = 0. 05, which indicated the difference was not statistically significant. And there were also no significant difference on the HR of 3-year OS, 3-year DFS, 5-year OS and 5-year DFS, and their RR were 1.18(95% CI 0. 84 ～ 1.66) ,1.31 (95% CI 0. 96 ～ 1.78) ,0. 89(95% CI 0. 68 ～ 1.15) ,and 0. 99(95% CI 0. 71 ～ 1.93) respectively. Conclusion For local advanced cervical cancer, NACT could reduce pathological risk factors but it did not improve the survival.
